Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Daily Archives: December 21, 2020

December 21, Epichem Awarded DNDi Extension

News & Announcements 2020By Richard Mollard December 21, 2020

201221_EpichemDNDi

Recent Articles

February 15, Canine Monepantel Phase IIb Lymphoma Trial Update
February 14, 2021
February 10, LUMC Covid-19 Research Update
February 10, 2021
January 31, Top 20 Shareholders
February 1, 2021
January 27, Appendix 4C and Quarterly Update
January 27, 2021

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

Retweet on Twitter PharmAust Retweeted

Hills to Hawkesbury Community News @H2HNews1·

The #AnimalReferralHospital is recruiting dogs with B cell lymphoma for a Phase IIb trial evaluating a newly formulated anti-cancer drug Monepantel (MPL), by biotech company @PharmAust

https://hillstohawkesbury.com.au/anti-cancer-drug-trial-for-dogs

Reply on Twitter 1364807083359690754 Retweet on Twitter 13648070833596907541 Like on Twitter 13648070833596907542 Twitter 1364807083359690754

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions